Advertisement

Tasimelteon

Chapter
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

The role of the melatonin in relation with circadian rhythms and the sleep/wake cycle is well established. It is thought to play a role in controlling the sleep–wake cycle through physiological processes regulated in the suprachiasmatic nucleus of the hypothalamus. In normal subjects, the endogenous circadian period is a little over 24 h, but is entrained to the 24-h day through exposure to light. In the absence of light or light perception (totally blind), the synchronization is lost and the circadian rhythm follows the intrinsic non-24 h clock, resulting in a non-24 h sleep–wake disorder. Non-24 h sleep–wake disorder is characterized by a misalignment of the 24-h light/dark (LD) cycle and a non-entrained sleep/wake cycle propensity resulting in asymptomatic periods alternating with episodes of insomnia, excessive daytime sleepiness (EDS), or a combination of both. Tasimelteon (VEC-162) is an orally bioavailable melatonin receptor agonist of the melatonin MT1 and MT2 receptors recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24 h sleep–wake rhythm disorder.

Keywords

Circadian System Primary Insomnia Moderate Hepatic Impairment Nighttime Sleep Blind Individual 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. AASM (2014) International classification of sleep disorders, 3rd ednGoogle Scholar
  2. American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, Darien, ILGoogle Scholar
  3. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (2005) The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20(12):1151–1158. doi: 10.1111/j.1525-1497.2005.0243.x PubMedCentralPubMedCrossRefGoogle Scholar
  4. Cardinali DP, Pandi-Perumal SR, Niles LP, Brown GM (2010) Melatonin and sleep: possible involvement of GABAergic mechanisms. In: Monti JM, Pandi-Perumal SR, Mohler H (eds) GABA and sleep. Springer, SwitzerlandGoogle Scholar
  5. Dhillon S, Clarke M (2014) Tasimelteon: first global approval. Drugs 74(4):505–511. doi: 10.1007/s40265-014-0200-1 PubMedCrossRefGoogle Scholar
  6. Dressman MA, Licamele L, Feeney J, Polymeropoulos MH (2012) Seventy percent of totally blind people with sleep complaints are not entrained to the 24 hour clock. Vanda Pharmaceuticals Inc., Washington, DCGoogle Scholar
  7. Hardeland R, Pandi-Perumal SR, Cardinali DP (2006) Melatonin. Int J Biochem Cell Biol 38(3):313–316. doi: 10.1016/j.biocel.2005.08.020 PubMedCrossRefGoogle Scholar
  8. Keijzer H, Smits MG, Duffy JF, Curfs LM (2013) Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders. Sleep Med Rev 18(4):333–339. doi: 10.1016/j.smrv.2013.12.001 PubMedCrossRefGoogle Scholar
  9. Lankford DA (2011) Tasimelteon for insomnia. Expert Opin Investig Drugs 20(7):987–993. doi: 10.1517/13543784.2011.583235 PubMedCrossRefGoogle Scholar
  10. Lewy AJ (2003) Clinical applications of melatonin in circadian disorders. Dialogues Clin Neurosci 5(4):399–413PubMedCentralPubMedGoogle Scholar
  11. Lewy AJ, Emens J, Sack RL, Hasler BP, Bernert RA (2003) Zeitgeber hierarchy in humans: resetting the circadian phase positions of blind people using melatonin. Chronobiol Int 20(5):837–852PubMedCrossRefGoogle Scholar
  12. Lockley SW, Skene DJ, James K, Thapan K, Wright J, Arendt J (2000) Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol 164(1):R1–R6PubMedCrossRefGoogle Scholar
  13. Lockley SW, Dressman MA, Xiao C, Fisher DM, Torres R, Lavedan C, Licamele L, Polymeropoulos MH (2013a) Tasimelteon treatment entrains the circadian clock and demonstrates a clinically meaningful benefit in totally blind individuals with non-24-hour circadian rhythms. In: 95th Annual meeting of the endocrine society, Abstract SUN-134Google Scholar
  14. Lockley SW, Dressman MA, Xiao C, Licamele L, Polymeropoulos MH (2013b) RESET study demonstrates that tasimelteon maintains entrainment of melatonin and cortisol in totally blind individuals with non-24-hour circadian rhythms. In: 95th Annual meeting of the endocrine society, Abstract SUN-137Google Scholar
  15. Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP (2005) Melatonin and sleep in aging population. Exp Gerontol 40(12):911–925. doi: 10.1016/j.exger.2005.08.009 PubMedCrossRefGoogle Scholar
  16. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R (2006) Melatonin: nature’s most versatile biological signal? FEBS J 273(13):2813–2838. doi: 10.1111/j.1742-4658.2006.05322.x PubMedCrossRefGoogle Scholar
  17. Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP (2007) Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 21(12):995–1018PubMedCrossRefGoogle Scholar
  18. Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB (2009) Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 373(9662):482–491PubMedCrossRefGoogle Scholar
  19. Sack RL, Lewy AJ (2001) Circadian rhythm sleep disorders: lessons from the blind. Sleep Med Rev 5(3):189–206. doi: 10.1053/smrv.2000.0147 PubMedCrossRefGoogle Scholar
  20. Smits MG, Pandi-Perumal SR, Warren Spence D, Brown GM (2010) Dim light melatonin onset (DLMO) in psychiatric disorders. In: Pandi-Perumal SR, Kramer MCUP (eds) Sleep and mental illness. Cambridge University Press, CambridgeGoogle Scholar
  21. VandaPharmaceuticals (2014) Tasimelteon Prescribing InformationGoogle Scholar
  22. Williamson BL, Tomlinson AJ, Mishra PK, Gleich GJ, Naylor S (1998) Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. Chem Res Toxicol 11(3):234–240. doi: 10.1021/tx970202h PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Johns Hopkins Bayview Medical CenterBaltimoreUSA
  2. 2.Department of Medicine, College of MedicineThe University Sleep Disorders Center, King Saud UniversityRiyadhSaudi Arabia
  3. 3.National Plan for Science and TechnologyKing Saud UniversityRiyadhSaudi Arabia
  4. 4.Division of Health and Behavior, Department of Population HealthClinical and Translational Research Institute, Center for Healthful Behavior Change, New York University Langone Medical CenterNew YorkUSA
  5. 5.Somnogen Canada Inc.TorontoCanada

Personalised recommendations